Sign Up
Stories
AnaMar Receives Orphan Drug Designation for AM1476
Share
Advancements in Cancer Treatment and Mar...
Amgen's Obesity Prospects in Focus
Autolus Thrives with $350M Offering and ...
4D Molecular Therapeutics Raises $300 Mi...
89bio to Present pegozafermin for NASH a...
ACTICOR BIOTECH: Financial Report Postpo...
Overview
API
AnaMar, a clinical-stage biotech company, has received orphan drug designation from the EMA and FDA for its lead clinical candidate, AM1476, for the treatment of systemic sclerosis. The company is planning Phase II clinical trials and seeking collaborations with pharma for the advancement of AM1476.
Ask a question
How could collaborations with pharma influence the progress and effectiveness of AM1476?
How might the orphan drug designation impact the development and potential success of AM1476?
What are the potential implications of AM1476's targeting of peripheral-acting 5-HT2B receptors for systemic sclerosis treatment?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Feb 2024
Coverage